ONS 2017 - Immunotherapy
Breast cancer is the second leading cause of cancer-related deaths in women in the United States. Despite the increase in survival with trastuzumab in the adjuvant setting, up to 26% of patients with early-stage HER2+ breast cancer experience disease recurrence within 5 to 8 years. The interim analysis after 5 years of follow-up in the ExteNET trial is presented.
Adherence to prescribed therapy is pivotal in cancer treatment. To ensure that patients receive the full benefit of their prescribed therapy, nurses and nurse practitioners play a critical role in identifying adverse events and implementing effective interventions that balance efficacy and tolerability.
Nivolumab is an immune checkpoint inhibitor approved for the treatment of patients with relapsed or refractory classical Hodgkin lymphoma. This immunotherapeutic agent is associated with immune-related adverse events that require prompt identification for successful management and resolution.
The use of monoclonal antibodies in the treatment of cancer is rapidly evolving. These immunomodulating agents are associated with an increased incidence of hypersensitivity reaction. Prompt identification and effective management is essential for optimal patient care.
Results 1 - 10 of 16